Works matching IS 11727047 AND DT 2022 AND VI 36 AND IP 8

Results: 7

Correction to: Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

Published in:

2022

By:

Sorensen, Per Soelberg

Publication type:

Correction Notice

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.

Published in:

CNS Drugs, 2022, v. 36, n. 8, p. 897, doi. 10.1007/s40263-022-00938-w

By:

Nasser, Azmi;
Hull, Joseph T.;
Chaturvedi, Soumya A.;
Liranso, Tesfaye;
Odebo, Oyinkansola;
Kosheleff, Alisa R.;
Fry, Nicholas;
Cutler, Andrew J.;
Rubin, Jonathan;
Schwabe, Stefan;
Childress, Ann

Publication type:

Article

Efficacy and Safety of Multiple Sclerosis Drugs Approved Since 2018 and Future Developments.

Published in:

CNS Drugs, 2022, v. 36, n. 8, p. 803, doi. 10.1007/s40263-022-00939-9

By:

Faissner, Simon;
Gold, Ralf

Publication type:

Article

Antiseizure Drugs and Movement Disorders.

Published in:

CNS Drugs, 2022, v. 36, n. 8, p. 859, doi. 10.1007/s40263-022-00937-x

By:

Sáenz-Farret, Michel;
Tijssen, Marina A. J.;
Eliashiv, Dawn;
Fisher, Robert S.;
Sethi, Kapil;
Fasano, Alfonso

Publication type:

Article

The Options for Neuraxial Drug Administration.

Published in:

2022

By:

Hermanns, Henning;
Bos, Elke M. E.;
van Zuylen, Mark L.;
Hollmann, Markus W.;
Stevens, Markus F.

Publication type:

journal article

Progress and Pitfalls in Developing Agents to Treat Neurocognitive Deficits Associated with Schizophrenia.

Published in:

2022

By:

Veselinović, Tanja;
Neuner, Irene

Publication type:

journal article

The Purinergic System as a Target for the Development of Treatments for Bipolar Disorder.

Published in:

2022

By:

Gonçalves, Maria Carolina Bittencourt;
Andrejew, Roberta;
Gubert, Carolina

Publication type:

journal article